Ibrutinib Racemate
Product Name :
Ibrutinib Racemate
Description:
Ibrutinib, also known as PCI-32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. Ibrutinib was approved by the US FDA on November 13, 2013 for the treatment of mantle cell lymphoma.
CAS:
936563-87-0
Molecular Weight:
440.50
Formula:
C25H24N6O2
Chemical Name:
1-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-ylprop-2-en-1-one
Smiles :
C=CC(=O)N1CC(CCC1)N1N=C(C2=C(N)N=CN=C12)C1C=CC(=CC=1)OC1C=CC=CC=1
InChiKey:
XYFPWWZEPKGCCK-UHFFFAOYSA-N
InChi :
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Ibrutinib, also known as PCI-32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. Ibrutinib was approved by the US FDA on November 13, 2013 for the treatment of mantle cell lymphoma.|Product information|CAS Number: 936563-87-0|Molecular Weight: 440.50|Formula: C25H24N6O2|Synonym:|Ibrutinib Racemate|PCI32765 Racemate|PCI 32765 Racemate|Chemical Name: 1-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-ylprop-2-en-1-one|Smiles: C=CC(=O)N1CC(CCC1)N1N=C(C2=C(N)N=CN=C12)C1C=CC(=CC=1)OC1C=CC=CC=1|InChiKey: XYFPWWZEPKGCCK-UHFFFAOYSA-N|InChi: InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Rotenone site |Shelf Life: ≥12 months if stored properly.Apolipoprotein A-I Protein, Human custom synthesis |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:32310458 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|PCI-32765 Racemate is oral effective in vivo. It induces lymphocytosis during the first weeks of therapy in patients with CLL. It is also efficacious in autoimmune disease. In the MRL-Fas lupus model, PCI-32765 inhibits collagen-induced arthritis as well as autoantibody production and development of kidney disease. It also diminished FcγRIII-induced production of pro-inflammatory cytokines.|References:|Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013 Nov;54(11):2385-91.Products are for research use only. Not for human use.|